Few combinations appear as often in growth hormone research as CJC-1295 and ipamorelin. Studied individually, each compound influences growth hormone signaling in a different way. Studied together, they represent one of the most discussed examples of how two peptides can be paired to explore a single biological system from two angles.
This guide explains what CJC-1295 and ipamorelin are, how each works, why researchers so often study them as a pair, and what to look for when sourcing them for laboratory research.
What Is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone–releasing hormone (GHRH) — the natural signal that prompts the pituitary gland to release growth hormone (GH).
Like other GHRH analogs, CJC-1295 is studied for its ability to stimulate GH release while remaining more stable than the natural hormone, which the body breaks down within minutes. This extended stability is a large part of why CJC-1295 became a research staple: it allows the GHRH pathway to be studied over a longer, more measurable window.
What Is Ipamorelin?
Ipamorelin belongs to a different class known as growth hormone secretagogues. Rather than acting on the GHRH receptor, it works through the ghrelin / GH-secretagogue receptor — a separate pathway that also influences growth hormone release.
Ipamorelin is frequently described in research as a “selective” secretagogue because, in study models, it is examined for stimulating GH signaling with comparatively limited effect on other hormones. That selectivity is why it appears so often in controlled research alongside a GHRH analog.
Why CJC-1295 and Ipamorelin Are Studied Together
The two compounds are paired because they approach growth hormone release through two different doors:
• CJC-1295 acts on the GHRH receptor.
• Ipamorelin acts on the ghrelin / GH-secretagogue receptor.
Because these are distinct signaling pathways, researchers study the combination to understand how simultaneous activation of both systems compares with activating either one alone. It’s a classic example of the multi-pathway thinking that also drives interest in compounds like retatrutide on the metabolic side — different receptors, studied together, to observe how signaling systems interact.
How the Combination Works (Mechanism)
At a mechanistic level, the combination is studied for how it engages the hypothalamic–pituitary axis from two directions at once:
• CJC-1295 provides a GHRH-style signal to the pituitary
• Ipamorelin adds a secretagogue signal through a separate receptor
• Together, researchers examine their combined influence on GH pulses and downstream IGF-1 activity
Because both compounds work with the pituitary rather than introducing growth hormone directly, the body’s own regulatory feedback remains part of the picture — a recurring theme across the growth hormone research category.
What Researchers Study It For
CJC-1295 and ipamorelin are examined across several research directions, including:
• Growth hormone / IGF-1 pathway activity — how paired signaling influences the GH axis
• Recovery and tissue-related research — GH signaling’s role in repair processes
• Metabolic and body-composition models — how GH interacts with fat and lean mass
• Sleep and circadian research — GH release is closely tied to sleep cycles
As always in this space, the value is repeatable observation under controlled conditions — not consumer claims.
CJC-1295/Ipamorelin vs Tesamorelin
A common question is how this combination compares with a single GHRH analog like tesamorelin.
• Tesamorelin is studied as a focused GHRH-pathway compound.
• CJC-1295 is also a GHRH analog, often noted for extended activity.
• Ipamorelin adds a second pathway (the secretagogue receptor) that neither GHRH analog engages.
In short, tesamorelin explores one door; CJC-1295/ipamorelin explores two at once. For a deeper look at the single-analog approach, see our overview of what tesamorelin is.
Handling and Reconstitution
Like most research peptides, CJC-1295/ipamorelin is supplied as a lyophilized (freeze-dried) powder that is reconstituted before use in a research setting.
General handling considerations include:
• Reconstitution with an appropriate diluent such as bacteriostatic water
• Gentle handling to preserve peptide stability
• Cool, controlled storage conditions
To work out concentrations for a given research protocol, our free Research Reconstitution Calculator is built for exactly that. Reconstitution guidance is provided solely for product handling and storage consistency — researchers are responsible for determining appropriate protocols for their specific applications.
Quality and Third-Party Testing
Growth hormone research depends on knowing exactly what is in the vial. Every C2 Peptides compound — including CJC-1295/ipamorelin — is third-party tested, with a Certificate of Analysis (COA) available for verification.
If you’re new to interpreting these documents, our guide on how to read a peptide Certificate of Analysis explains what purity and identity testing actually confirm before research use.
Frequently Asked Questions
What are CJC-1295 and ipamorelin?
CJC-1295 is a GHRH analog and ipamorelin is a growth hormone secretagogue. Both are studied for their role in growth hormone signaling, through two different receptor pathways.
Why are CJC-1295 and ipamorelin used together?
They activate growth hormone release through separate pathways — the GHRH receptor and the ghrelin/secretagogue receptor — so researchers study the pair to observe how the two systems interact.
How is ipamorelin different from CJC-1295?
CJC-1295 mimics the natural GHRH signal, while ipamorelin works through a distinct secretagogue receptor and is often described as selective in research models.
How does this combination compare to tesamorelin?
Tesamorelin is a single GHRH analog, while CJC-1295/ipamorelin engages two pathways at once. They represent single-pathway vs. multi-pathway research approaches.
Explore Growth Hormone Research Peptides
CJC-1295 and ipamorelin remain one of the most-studied pairings in the field. You can view CJC-1295/Ipamorelin here or browse the full Growth Hormone Research collection.
For more research overviews, explore all C2 Peptides articles.
The statements on this website have not been evaluated by the U.S. Food and Drug Administration. The products and information provided by C2 Peptides are not intended to diagnose, treat, cure, or prevent any disease. All products are sold for research, laboratory, or analytical purposes only, and are NOT for human consumption.